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Abstract
Background: Spinal cord injury (SCI) is a devastating condition with substantial functional and social morbidity.
Previous research has established that the neuroinflammatory response plays a significant role in cord damage post-SCI.
However, global immunosuppressive therapies have demonstrated mixed results. As a result, more specific therapies
modulating inflammation after injury are needed. In this regard, research into cytokine signaling has demonstrated that
cytokines of the gp130 family including IL-6 and leukemia inhibitory factor (LIF) play key roles in mediating damage to
the spinal cord. Since members of the gp130 family all share a common signal transduction pathway via the JAK/STAT
system, we performed the first study of a relatively new member of the gp130 family, IL-11, in SCI.
Methods: A validated clip-compression mouse model of SCI was used to assess for temporal changes in expression of
IL-11 and its receptor, IL-11Rα, post-SCI. To elucidate the role of IL-II in the pathophysiology of SCI, we compared
differences in locomotor recovery (Basso Mouse Score; CatWalk), electrophysiological spinal cord signaling, histopathology,
and the acute inflammatory neutrophil response in IL-11Rα knockouts with littermate wild-type C57BL/6 mice.
Results:We found an increase in gene expression of IL-11 in the spinal cord to a peak at twenty-four hours post-SCI with
increases in IL-11Rα gene expression, peaking at seven days post-SCI. In spite of clear changes in the temporal expression
of both IL-11 and its receptor, we found that there were no significant differences in motor function, electrophysiological
signaling, histopathology, or neutrophil infiltration into the spinal cord between wild-type and knockout mice.
Conclusions: This is the first study to address IL-11 in SCI. This study provides evidence that IL-11 signaling may not play
as significant a role in SCI as other gp130 cytokines, which will ideally guide future therapy design and the signaling
pathways those therapies target.
Keywords: Spinal cord injury, IL-11, mouse model, locomotor recovery, gp130 receptor, immune response,
electrophysiology
Background
Spinal cord injury (SCI) is a devastating condition,
which is associated with severe physical burden in
addition to psychological, social, and economic stress
[1]. Despite improvements in the understanding of the
pathophysiology of SCI, there are currently no robustly
effective treatments to improve neurological function in
this condition [1].
As a result, various methods to prevent and reduce
morbidity and mortality after SCI have been or are in
the process of being investigated. In this regard, research
has demonstrated that SCI is a biphasic process consist-
ing of a primary injury characterized by contusion, com-
pression, or transection of the spinal cord followed by a
secondary injury phase that exacerbates the initial pri-
mary insult including apoptosis, ischemia of the spinal
cord, and inflammation [1-3]. Neuroinflammation, via
cytokine signaling and cellular infiltration into the cord,
plays a significant role in secondary damage following
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SCI [3]. Hence, therapies aimed at mitigating the neu-
roinflammatory response have logically been candidates
for spinal cord neuroprotection and repair. Global im-
munosuppressive therapies such as methylprednisolone
have been attempted but with mixed results [3-5].
More specific therapies aimed at inflammation post-SCI
are thus needed. In this respect, to further understand
the signaling dynamics of inflammation in mediating
damage after SCI, the gp130 receptor family of cytokines
has been the subject of an increasing amount of re-
search. This family of cytokines all shares the gp130
membrane glycoprotein as a common signal transducer,
which then results in signal transduction via the Janus
kinase/signal transducers and activators of transcription
(JAK/STAT) pathway [6]. This family of cytokines
includes IL-6 and leukemia inhibitory factor (LIF), which
have been shown to play pivotal roles in SCI. IL-6 has
been shown to play a central role in mediating pro-
inflammatory damage after SCI [7-9]. LIF has been
shown to have both pro-inflammatory and oligodendro-
cyte preservation effects after SCI [10-12]. STAT3 has
also been shown to play an important role in regulating
reactive astrocyte migration and responses after SCI
[13,14]. This body of evidence suggests that the gp130
receptor and its associated cytokines and signaling path-
ways play an important role in SCI.
To further understand cytokine signaling in this family
and SCI, a relatively novel member of the gp130 family,
IL-11, was addressed in this study. IL-11 interacts with
its ligand-specific cell surface receptor subunit IL-11Rα
that then couples to gp130 and results in activation of
JAK/STAT signaling [15]. In situ hybridization has
demonstrated IL-11 expression in the hippocampus and
ventral area of the spinal cord [15]. IL-11 has also been
shown to play an immunomodulatory role in an experi-
mental autoimmune encephalomyelitis (EAE) model for
multiple sclerosis with increased inflammation, demyelin-
ation, and oligodendrocyte and neuronal loss in IL-11Rα-
deficient mice [16]. Moreover, IL-11 has been shown to
play a role in mediating oligodendrocyte viability and
maturation in primary human fetal oligodendrocyte-
enriched cultures [17]. No previous studies to date have
addressed the role of IL-11 in SCI.
With the limited number of studies of IL-11 in the
central nervous system, we hypothesized that IL-11
would play an anti-inflammatory role and a role in oligo-
dendrocyte preservation after SCI, resulting in worsened
neurobehavioral outcomes with decreases in IL-11 sig-
naling. We thus subjected IL-11Rα-deficient mice and
wild-type littermate mice to SCI using a validated clip
compression injury model [18-20] and assessed for dif-
ferences in motor function, histopathology, electro-
physiological signaling, and neutrophil infiltration in the
spinal cord. This study is the first study to address the
role of IL-11 in SCI and hopefully will provide a basis
for future research in understanding the role of the
gp130 family of cytokines in inflammation after injury.
Ultimately, this understanding will hopefully lead to bet-
ter therapies aimed at modulating cytokine signaling and
decreasing damaging inflammatory processes after SCI.
Methods
Animals used and experimental groups
All experimental protocols were approved by the Animal
Care Committee at the Toronto Western Research Insti-
tute in accordance with the policies of the Guide to the
Care and Use of Experimental Animals as per the Can-
adian Council of Animal Care.
Female, adult wild-type C57BL/6 mice (15 to 20 g;
Jackson Laboratories, Bar Harbor, ME, USA) aged eight
to twelve weeks and littermate IL-11Rα knockout
(IL-11Rα-deficient) mice fully congenic on a C57BL/6
background (strain B6.129S1-Il11ra1tm1Wehi/J; Jack-
son Laboratories) were used for behavioral analysis,
histology, electrophysiology, and assessment of the in-
flammatory response after SCI. All genotyping was per-
formed by Jackson Laboratories before delivering mice to
our site. Wild-type female, adult C57BL/6 mice of similar
weight and age were also purchased separately (Jackson
Laboratories) for RT-PCR and ELISA analyses.
The overall study divided mice into two broad cohorts:
1) analysis of the gene and protein changes after SCI of
IL-11 and IL-11Rα and 2) comparison of wild-type and
IL-11Rα-deficient mice in terms of functional, histo-
logical, and inflammatory outcomes after SCI. To meet
the first objective, a total of 65 wild-type C57BL/6 mice
were used. To study the temporal changes in gene ex-
pression of IL-11 and IL-11Rα after SCI, animals were
divided into six groups: uninjured control (n = 5), four
hours post-SCI (n = 5), eight hours post-SCI (n = 5),
twenty-four hours post-SCI (n = 5), three days post-SCI
(n = 5), and seven days post-SCI (n = 5). To study the
temporal changes in protein expression of IL-11 after
SCI, animals were again divided into six groups: unin-
jured control (n = 5), four hours post-SCI (n = 6), eight
hours post-SCI (n = 6), twenty-four hours post-SCI
(n = 6), three days post-SCI (n = 6), and seven days post-
SCI (n = 6). To meet the second objective, two groups of
animals were used (total n = 47): IL-11Rα-deficient
C57BL/6 mice (n = 11) and wild-type littermate C57BL/6
mice (n = 13) for behavioral analysis. The behavior of
these mice was followed for six weeks followed by elec-
trophysiological recordings of these mice at six weeks
after which the mice were sacrificed and then analyzed
for histological characterization. Another set of unin-
jured IL-11Rα-deficient mice (n = 4) and uninjured
wild-type littermate mice (n = 4) were used for electro-
physiological recordings as control animals. Finally,
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another set of injured IL-11Rα-deficient mice (n = 5) and
injured wild-type littermate mice (n = 5) and a separate
set of uninjured control wild-type C57BL/6 mice (n = 5)
were used to compare the inflammatory response be-
tween these mice after SCI.
Spinal cord injury
Anesthesia in the mice was first induced with a mixture
of isoflurane (1 to 4%), nitrous oxide, and oxygen (1:1/
minute) in a chamber and then maintained using a mask
integrated in a stereotaxic surgical frame. Surgery did
not commence until the mice were no longer responsive
to a nociceptive stimulus. Before surgery, a subcutane-
ous bolus of 0.5 mL of saline was given, and for the dur-
ation of the surgery, mice were placed on a heating pad
at 37°C. Under aseptic conditions, the hair on the skin
on the back of the mouse was shaved off and disinfected
with a 1:1 mixture of 70% alcohol and iodine. A midline
skin incision was then made to expose the superficial
back muscle layers. The muscle attached to the vertebrae
was dissected away using a No. 15 scalpel blade to ex-
pose the T7-T9 vertebrae. Laminectomy forceps were
used to perform a laminectomy at T7-T9, and a dissect-
ing hook was used to gently clear an extradural path on
the ventral side of the spinal cord between T7-T8 with-
out damaging the underlying spinal cord. The spinal
cord was compressed extradurally at T7-T8 ventrally
and dorsally using a modified aneurysm clip (FejotaTM
mouse clip; University Health Network, Toronto,
Canada) that was passed around the spinal cord in the
path created using the dissecting hook. The clip was
released rapidly with a closing force of 8.5 grams and
was allowed to compress the cord for 30 seconds before
being removed, resulting in a moderate SCI. Surgeries
involving knockout mice and their wild-type littermates
were performed in alternation. Mice to be used in long-
term behavioral characterization also had a piece of ster-
ile absorbable gelatin sponge (Gelfoam; Pfizer Inc., New
York, NY, USA) placed over the dura between T7-T9 to
avoid excessive scar formation over the cord in the long
term. Uninjured control mice did not receive any injury
or laminectomy.
After completion of the surgery, the superficial muscle
layers were sutured together followed by closing of the
skin incision using small Michel clips. Antibiotic cream
(Polysporin; Johnson & Johnson Inc., New Brunswick,
NJ, USA) was then generously applied over the area of
the skin incision. 1.0 mL of saline was also immediately
administered subcutaneously to replace blood volume
lost during the procedure as well as 0.1 mL of buprenor-
phine (0.05 mg/kg) subcutaneously to alleviate post-
operative pain. During recovery from anesthesia, mice
were also placed in new sterile cages under a heating
lamp and eventually housed in a temperature-controlled
room at 27°C for as long as required during experimen-
tation. Food and water were provided ad libitum, and
the mice received antibiotic in their drinking water (Cla-
vamox drops; Pfizer Animal Health, New York, NY,
USA). Buprenorphine was subcutaneously administered
twice daily for three more days after surgery. Bladders
were manually voided twice daily until bladder function
returned.
Real-time PCR (RT-PCR)
Mice were overdosed with isoflurane. Each animal was
then perfused intracardially with 30 mL of RNase-free
Ringer’s solution at 4°C. The spinal column was then
dissected out of the mouse and immediately placed in
RNase-free Ringer’s solution at 4°C. A spinal cord sec-
tion of 0.5 cm centering on the lesion epicenter was then
isolated after removal of dura mater around the cord,
and the cord was frozen on dry ice. The spinal cord
samples were then manually ground and homogenized
in Trizol (Invitrogen Co., Carlsbad, CA, USA), and RNA
extraction was completed according to the manufac-
turer’s instructions (Qiagen Inc., Toronto, Canada). RNA
concentration was determined using the NanoDrop
spectrophotometer (Thermo Fisher Scientific, Wilming-
ton, DE, USA). cDNA synthesis was then performed
using the SuperScript III Reverse Transcriptase kit
according to the manufacturer’s instructions (Invitrogen
Co.). RT-PCR was then carried out on a 396-well plate
with each well containing cDNA, appropriate forward
and reverse primers (Table 1) for IL-11, IL-11Rα, and
HPRT (Integrated DNA Technologies Inc., Coralville,
IA, USA), nuclease-free water, and SYBR Green (Applied
Biosystems, Foster City, CA, USA). Each sample was run
in triplicates for each gene, and fold change analysis was
standardized to hypoxanthine phosphoribosyltransferase
(HPRT).
ELISA
Mice were overdosed with isoflurane. Each animal was
then perfused intracardially with 30 mL of saline (0.9%
NaCl) at 4°C. The spinal column was then dissected out
of the mouse and immediately placed in saline at 4°C. A
Table 1 Sequences of primers used to amplify mouse
IL-11, IL-11Rα, and HPRT
Primer name Sequence
Forward IL-11 5′-AAT TCC CAG CTG ACG GAG ATC ACA-3′
Reverse IL-11 5′-TCT ACT CGA AGC CTT GTC AGC ACA-3′
Forward IL-11Rα 5′-TGG AAG TCC ACC TGA GGA ATG TGT-3′
Reverse IL-11Rα 5′-AGA CCG CAC ACA CTC TCC AAT CAT-3′
Forward HPRT 5′-AGG AGT CCT GTT GAT GTT GCC AGT-3′
Reverse HPRT 5′-GGG ACG CAG CAA CTG ACA TTT CTA-3′
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spinal cord section of 0.5 cm centering on the lesion epi-
center was then isolated after removal of dura mater
around the cord, and the cord was frozen on dry ice.
The spinal cord samples were then manually ground and
homogenized in RIPA buffer containing a cocktail of
EDTA and protease inhibitors (5 mM Tris-HCl, 4 mM
EDTA, 1 μM pepstatin, 100 μM leupeptin, 100 μM phe-
nylmethylsulfonyl fluoride, and 10 μg/mL aprotinin) at
4°C. Total protein concentrations of each of the samples
was then determined via the Lowry method. A 96-well
ELISA plate (Nunc-Immuno Plates MaxiSorp; Thermo
Fisher Scientific, Rochester, NY, USA) was then prepared
and samples and reagents added as per manufacturer’s
instructions for the mouse IL-11 DuoSet ELISA Devel-
opment System kit (catalog number DY418; R & D Sys-
tems Inc., Minneapolis, MN, USA). Each sample was
run in duplicate.
Assessment of motor function recovery
Motor function recovery comparisons between wild-type
and IL-11Rα-deficient mice were performed using two
motor tests: Basso Mouse Scale (BMS) and the CatWalk
gait analysis system.
The Basso Mouse Scale (BMS) is a validated scale to
monitor the progress of hindlimb functional recovery
after SCI [21]. The scale extends from 0 to 9 (0 = no
ankle movement and 9 = normal locomotion) and
involved the observation of each mouse in an open field
for four minutes by two observers. The observers were
blinded to the genetic identity of each mouse. Each
hindlimb was scored individually, and the scores of each
hindlimb were then averaged to create a score for the
entire animal. Animals were observed at three days post-
injury and then seven days post-injury and, from then
on, observed weekly for a total of six weeks post-injury.
Subscore analysis was also performed at the above time
points for animals that achieved frequent plantar step-
ping (BMS score of 5 and above). The BMS subscore
scale extends from 0 to 11 and is generally used to de-
tect differences between animals that have reached a
plateau at similar levels on the main BMS [21]. Animals
that had not reached frequent plantar stepping were
scored as 0 according to the subscore scale.
Gait analysis using the CatWalk gait analysis system
was performed at six weeks post-injury to further com-
pare wild-type with IL-11Rα-deficient mice. The Cat-
Walk gait analysis system assesses gait parameters such
as stride length, regularity index (measure of coordin-
ation), print area, swing speed, and base of support that
are not assessed by the Basso Mouse Scale, providing a
further level of characterization of any gait differences
and functional recovery between wild-type and IL-11Rα-
deficient mice [22]. Only animals that had reached fre-
quent plantar stepping on the Basso Mouse Scale were
analyzed using the CatWalk gait analysis system as the
system requires the mouse to step across a platform for
the analysis.
Sensory evoked potential recordings
Six weeks post-injury, sensory evoked potentials (SEPs)
were recorded from 18 mice (uninjured IL-11Rα-
deficient mice, n = 4; uninjured wild-type C57BL/6 mice,
n = 4; injured IL-11Rα-deficient mice, n = 5; injured wild-
type C57BL/6 mice, n = 5). The evoked potentials were
recorded using stainless steel needle electrodes and a
Keypoint Portable System. Mice were anesthetized using
a mixture of isoflurane (1 to 4%), nitrous oxide and oxy-
gen (1:1/minute) in a chamber and then maintained
using a mask integrated in a stereotaxic frame. The
recording electrodes were positioned extradurally over
the spinal cord at C2 and C3. Two stainless steel record-
ing electrodes were inserted into the hindpaw. A ground
electrode was inserted subcutaneously between the
stimulating and recording electrodes. A constant current
stimulus of 0.1 ms duration and 2.0 mA intensity was
applied at a rate of 5.7 Hz to the hindpaw. At a band-
width of 10 to 3000 Hz, a total of 300 traces were aver-
aged and replicated. SEP peak latency was measured
from the start of the stimulus (S) to the peak of the first
positive peak (P1).
Histopathology
Mice were overdosed with isoflurane. The mice were
then perfused intracardially with 10 mL of phosphate-
buffered saline (PBS) followed by 30 mL of paraformal-
dehyde (4%w/v in PBS, pH 7.4) at 4°C. The spinal cords
were then dissected out from each mouse and post-fixed
overnight in 10% sucrose/4% paraformaldehyde solution
at 4°C. The spinal cords were then cryoprotected by pla-
cing the cords in 20% sucrose solution in PBS for 24
hours at 4°C. A 1.0 cm length of spinal cord centered at
the injury epicenter was then embedded in Tissue-Tek
Optimal Cutting Temperature compound (OCT; Sakura
Finetek USA Inc., Torrance, CA, USA) and stored at
−80°C.
Serial transverse sections of 20 μm thickness were
then prepared for each spinal cord to be analyzed and
mounted on glass slides and stored at −80°C. A total of
five injured knockout mice and five injured littermate
wild-type mice at six weeks post-injury were analyzed
and compared. Serial spinal cord sections spaced
120 μm apart were stained with Luxol Fast Blue (LFB)
and hematoxylin/eosin (H and E) for each animal span-
ning 600 μm rostral and caudal to the injury epicenter.
Tissue sections were first dried at room temperature for
one hour and submerged in PBS for one minute to re-
move any excess OCT. The sections were then dipped in
50% ethanol for one minute and then placed in LFB
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overnight at 56°C. The following day, the sections were
then dipped in 95% ethanol for five minutes followed by
ddH2O for five minutes. The sections were then
destained in 0.05% LiCO2 followed by a dip in 70% etha-
nol for 30 seconds. The sections were then again placed
in ddH2O for five minutes. After, the sections were
dipped in hematoxylin for 20 minutes followed by a rins-
ing step with tap water for 10 minutes. The sections
were then dipped in eosin for five seconds followed by
two five-minute dips in 95% ethanol and two five-
minute dips in 100% ethanol. Finally, the sections were
subjected to three five-minute dips in xylene and then
cover slipped.
The injury epicenter was defined as the section with
the largest area of scar/vacuolation tissue and least
amount of grey matter. Tissue sections were analyzed
for scar (defined as fibrous and inconsistent tissue
matrix), grey matter sparing (stained red due to eosin),
and white matter sparing (stained blue due to LFB). Tis-
sue sections were analyzed using the Cavalieri Probe
(Stereo Investigator 64-bit software; MBF Bioscience,
Williston, VT, USA) and areas of scarring, grey matter,
and white matter were expressed as percentages of the
total area of each tissue section. Experimenters were
blinded to the genetic identity of the tissue sections.
Myeloperoxidase activity assay
Myeloperoxidase (MPO) activity was assayed using a
myeloperoxidase fluorometric detection kit according to
the manufacturer’s instructions (catalog number ADI-
907-029; Enzo Life Sciences International Inc., Plymouth
Meeting, PA, USA). Five wild-type and five knockout
mice were injured and their spinal cords extracted at 24
hours post-injury. Five uninjured wild-type mice spinal
cords were also assayed to serve as a control for any ab-
errant MPO activity that may be detected in the cords
due to methodological error. MPO is present in the
azurophilic granules of polymorphonuclear leukocytes
and is unique to neutrophils and monocytes. The time
point of 24 hours post-SCI was chosen given that neu-
trophil infiltration into the spinal cord peaks at this time
after SCI in the mouse and rat [23]. Briefly, the mice
were overdosed with isoflurane. The mice were then per-
fused intracardially with 30 mL of saline (0.9% NaCl) at
4°C. The spinal column was then dissected out of each
mouse and immediately placed in saline at 4°C. A spinal
cord section of 0.5 cm centering on the lesion epicenter
was then isolated after removal of dura mater around
the cord, and the cord was frozen on dry ice. The spinal
cord samples were then manually ground and homoge-
nized in assay buffer provided in the MPO detection kit
containing 10 mM of N-ethylmaleimide (NEM). The
samples were centrifuged at 12 000 g for 20 minutes at
4°C and the supernatant removed and discarded. The
pellet was then resuspended in assay buffer with 10 mM
NEM and 0.5%w/v hexadecyltrimethylammonium
(HTA-Br), homogenized, and subjected to two freeze-
thaw cycles. The samples were then centrifuged at 8
000 g for 20 minutes at 4°C. The remaining supernatant
of each sample was then loaded into a 96-well plate with
detection reagent as specified by the manufacturer and
run in duplicate. The fluorometric reaction was allowed
to proceed for 60 minutes, and the fluorescence was
measured at an excitation wavelength of 530 to 570 nm
and emission wavelength at 590 to 600 nm.
Statistical analysis
All data are presented as mean ± standard error of the
mean (SEM). Gene and protein expression data, electro-
physiology latency data, and myeloperoxidase activity data
was analyzed using a one-way analysis of variance
(ANOVA). The Basso Mouse Scale and histology data was
analyzed using a two-way analysis of variance (ANOVA)
repeated measures. Significant ANOVA results were fol-
lowed by post hoc Bonferroni analysis. Pair-wise compari-
sons between wild-type and knockout mice for CatWalk
data were performed using Student’s t test. The signifi-
cance level of all analyses was set at P <0.05.
Results
IL-11 and IL-11Rα expression change after spinal cord
injury
To establish whether IL-11 and its associated receptor
IL-11Rα respond to SCI, RT-PCR and ELISA were used
to assess for changes in gene and protein expression at
various times post-injury. Any potential role for IL-11 in
SCI would logically be reflected in accompanying
changes in gene and protein expression post-injury. RT-
PCR analysis revealed that IL-11 gene expression
changes significantly after SCI (one-way ANOVA,
P= 0.002; Figure 1A). Post hoc analysis revealed that IL-
11 gene expression at 24 hours was significantly different
from uninjured control mice (P= 0.002) and gene ex-
pression at seven days (P= 0.005) while no other time
points were significantly different from uninjured mice
in the post hoc analysis, suggesting peak gene expression
at 24 hours. IL-11 gene expression changes were corro-
borated with ELISA data demonstrating a steady in-
crease in the amount of IL-11 present in the spinal
cord with time post-SCI (one-way ANOVA, P <0.001;
Figure 1B). Post hoc analysis revealed peak levels of IL-
11 at seven days post-SCI with significantly greater
amount of IL-11 compared to uninjured control mice
(P <0.001), mice at four hours (P <0.001), eight hours
(P <0.001), and twenty-four hours (P= 0.002) post-
SCI. Significant IL-11Rα gene expression changes also
occurred post-injury (one-way ANOVA, P <0.001;
Figure 1C). The pattern of increase in gene expression
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of IL-11Rα differed from that of IL-11 with post hoc
analysis revealing that gene expression was significantly
greater at three days and seven days relative to the other
time points and the uninjured control mice (P ≤0.001
relative to other time points for both three days and
seven days post-SCI). Moreover, the magnitude of the
fold change in gene expression differed between IL-11
and IL-11Rα post-injury. IL-11 demonstrated a peak
gene expression fold change at twenty-four hours post-
injury relative to uninjured control mice of 20.41 ± 6.75
while IL-11Rα demonstrated a fold change at three and
seven days post-injury relative to uninjured control mice
of only 2.12 ± 0.20 and 2.29 ± 0.16, respectively.
No difference between wild-type and IL-11Rα-deficient
mice was observed in hindlimb motor recovery
Wild-type and knockout mice were observed for loco-
motor recovery for six weeks post-injury using the Basso
Mouse Scale [21]. No significant differences in hindlimb
function as assessed using the BMS were found over six
weeks (two-way ANOVA repeated measures, P= 0.502;
Figure 2A). Functional improvement in both the wild-
type and knockout mice occurred until about twenty-
one days (three weeks) post-injury when recovery plat-
eaued. BMS subscore analysis also did not reveal any
differences between the wild-type and knockout mice
over six weeks (two-way ANOVA repeated measures,
P= 0.582; Figure 2B). The BMS subscores plateaued
relatively quickly at approximately fourteen days (two
weeks) post-injury. This was likely due to the fact that
the number of mice in both the wild-type and knockout
group who reached frequent plantar stepping and thus
were scored using the BMS subscore scale remained
constant from that time after injury for the duration of
the study, thus resulting in very little changes in the
overall BMS subscore scale scores.
CatWalk gait analysis was also performed at six weeks
post-SCI on mice that had received frequent plantar step-
ping on the BMS (score of 5 and above). The same num-
ber of wild-type and knockout mice (n= 5) achieved
frequent plantar stepping at six weeks post-SCI, and there
were no significant differences in the BMS scores between
these two groups of mice (data not shown). This allowed
for any true differences in gait using the CatWalk analysis
to be determined without any systematic bias due to dif-
ferences in gross hindlimb function as measured using the
BMS. The CatWalk gait analysis system provided another
degree of characterization of hindlimb motor recovery by
assessing parameters not addressed in the BMS [22]. Com-
parison of the gait between wild-type and knockout mice
revealed no differences in hindlimb print width (Student’s
t test, P=0.834), print length (Student’s t test, P=0.522),
stride length (Student’s t test, P=0.409), and base of sup-
port (Student’s t test, P=0.633; Figure 3A). There were
Figure 1 IL-11 and IL-11Rα expression is increased after spinal cord injury in wild-type mice. qRT-PCR for temporal gene expression of (A)
IL-11 in the spinal cord after SCI demonstrate a peak in gene expression at 24 hours, supported by increasing (B) IL-11 protein levels in the spinal
cord as measured via ELISA. qRT-PCR for temporal gene expression of (C) IL-11Rα also revealed an increase in gene expression with time after
injury with peak expression occurring later than IL-11. Data represent mean ± SEM (error bars), n = 5 for each uninjured group, n = 5 for time
points of qRT-PCR, n = 6 for time points of ELISA. *P <0.05 (one-way ANOVA followed by post hoc Bonferroni test).
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also no significant differences in swing time (Student’s t
test, P=0.889; Figure 3B) and regularity index (Student’s
t test, P=0.900; Figure 3C), which is a measure for
interlimb coordination. Figure 3D provides representa-
tive images of the footprints of the wild-type and
knockout mice.
Axonal conduction was not significantly different
between wild-type and IL-11Rα-deficient mice following
SCI
Sensory evoked potentials were recorded to assess
axonal function following injury in both wild-type (n = 5)
and IL-11Rα-deficient mice (n = 5) using the mice
analyzed in the CatWalk gait analysis component of the
study. In addition, evoked potentials were also recorded
from uninjured wild-type (n = 4) and IL-11Rα-deficient
mice (n = 4) to control for any inherent differences in
axonal conduction between wild-type and knockout
mice. One-way ANOVA analysis revealed that there
were significant differences in P1 peak latencies between
the four groups overall (P <0.0001, Figure 4). However,
post hoc analysis revealed no difference in peak latencies
between uninjured wild-type and IL-11Rα-deficient mice
(P= 1.000, Figure 4), suggesting no inherent differences
in axonal conduction between wild-type and knockout
mice. P1 latency was 1.31 ± 0.043 ms and 1.25 ± 0.029 ms
Figure 2 Hindlimb functional recovery is not significantly different between wild-type and IL-11Rα-deficient mice. (A) BMS and (B) BMS
subscore analysis revealed no significant differences between wild-type (n = 13) and IL-11Rα-deficient (n = 11) mice in hindlimb motor recovery
at the indicated time points up to six weeks (forty-two days) post-SCI (two-way repeated measures ANOVA). Data represent mean ± SEM
(error bars).
Figure 3 CatWalk gait analysis at six weeks (forty-two days) post-SCI revealed no significant difference between injured wild-type
(n= 5) and injured IL-11Rα-deficient (n = 5) mice in hindlimb. (A) Print width, print length, stride length, base of support, (B) swing time, and
(C) regularity index (Student’s t test). (D) Representative footprints from injured wild-type and injured knockout mice six weeks (forty-two days)
post-SCI. Data represent mean ± SEM (error bars).
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in uninjured wild-type and uninjured IL-11Rα-deficient
mice, respectively. However, both injured wild-type (P
<0.0001 relative to uninjured wild-type and uninjured
knockout) and injured IL-11Rα-deficient mice (P <0.05
relative to uninjured wild-type and uninjured knockout)
showed significant increases in P1 latency indicating
impaired axonal conduction. In wild-type mice, the P1
latency was increased to 3.94 ± 0.577 ms at six weeks
after SCI while the P1 latency was increased to
3.04 ± 0.112 ms in IL-11Rα-deficient mice. Although SCI
resulted in impaired axonal conduction in both the wild-
type and IL-11Rα-deficient mice, there was no
significant difference in axonal conduction following in-
jury between wild-type and IL-11Rα-deficient mice
(P= 0.376, Figure 4). The prominent peak recorded was
abolished following spinal cord transection below the
recording electrodes, indicating the spinal cord origin of
the recorded signals.
Spared tissue and lesion size did not differ between
wild-type and IL-11Rα-deficient mice
Spinal cord sections spaced 120 μm apart spanning
600 μm on each side of the injury epicenter were ana-
lyzed for the five wild-type and five knockout mice used
Figure 4 Sensory evoked potential (SEP) latencies demonstrated no significant difference between injured wild-type (n= 5) and injured
IL-11Rα-deficient mice (n = 5). (A) Representative average waveforms are provided for injured and uninjured wild-type and IL-11Rα-deficient
mice showing point of stimulation (S) and first positive peak (P1). (B) Both wild-type and knockout injured mice demonstrate significantly greater
latencies compared to both uninjured wild-type (n = 4) and uninjured knockout (n = 4) control mice while uninjured wild-type and uninjured
knockout mice do not demonstrate significant differences in latency from each other. Data represent mean ± SEM (error bars). *P <0.05 (one-way
ANOVA followed by post hoc Bonferroni test).
Figure 5 No significant differences in histopathology were observed at six weeks post-SCI between injured wild-type (n= 5) and
injured IL-11Rα-deficient (n = 5) mice. Histopathological analysis of spinal cord sections from both wild-type and IL-11Rα-deficient mice
revealed no significant differences in (A) scar tissue area, (B) grey matter area preservation, and (C) white matter area preservation (two-way
repeated measures ANOVA). Data represent mean ± SEM (error bars).
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in the CatWalk gait analysis component of the study to
assess for any possible histopathological differences due
to changes in IL-11 signaling six weeks post-SCI, despite
the lack of differences in hindlimb motor recovery and
evoked potentials. Unlike rat models of SCI, no promin-
ent cavitation was observed in the injured mouse spinal
cords analyzed in this study. Instead, the injured mouse
spinal cord lesions exhibited prominent disruption of
the tissue matrix and scar formation which included
most of the grey matter while sparing a rim of white
matter. Hematoxylin and eosin staining with LFB of
spinal cord sections with Cavalieri probing using Stereo
Investigator software was used to calculate areas of scar
formation, grey matter preservation, and white matter
preservation in successive spinal cord sections of each
animal analyzed. No significant differences between
wild-type and knockout mice were found for area of scar
(two-way ANOVA repeated measures, P= 0.738), grey
matter area preservation (two-way ANOVA repeated
measures, P= 0.540), and white matter area preservation
(two-way ANOVA repeated measures, P= 0.104) as seen
in Figure 5.
Myeloperoxidase activity in the injured spinal cord is not
different between wild-type and knockout mice
To assess for possible effects on inflammation that may
have not manifested as significant neurobehavioral, elec-
trophysiological, or histopathological outcomes, myelo-
peroxidase (MPO) activity in the spinal cord of wild-type
and knockout mice was compared 24 hours post-SCI
(Figure 6). Five wild-type and five knockout mice were
compared for MPO activity. Five uninjured control wild-
type mice were also analyzed to serve as a control for
any aberrant methodological errors that may have
affected the assay and resulted in inaccurate MPO read-
ings. Both the knockout (0.032 ± 0.005 U/g, P <0.05) and
wild-type (0.052 ± 0.009 U/g, P <0.001) injured mice had
significantly elevated MPO levels in their spinal cords
relative to the uninjured mice (0.007 ± 0.002 U/g), as
expected (one-way ANOVA P <0.001). However, no sig-
nificant difference was observed between the knockout
and wild-type injured mice from each other after post
hoc analysis (P= 0.157).
Discussion
Previous research has demonstrated that neuroinflam-
mation plays a prominent role in the secondary damage
that occurs to the spinal cord after injury. In this regard,
members of the gp130 family of cytokines (including IL-
6 and LIF) and its associated JAK/STAT signaling path-
way have been studied previously and have been shown
to play important roles in inflammation and functional
recovery after SCI [7-14]. IL-11, a newer member of the
gp130 family of cytokines, has recently been shown to
play an anti-inflammatory and neuroprotective role in
multiple sclerosis [16] and a role in mediating oligo-
dendrocyte viability and maturation in enriched primary
oligodendrocyte human fetal cultures [17]. Previous re-
search in other systems has also pointed to an anti-
inflammatory role of IL-11. IL-11 has been shown to
play an anti-inflammatory role in the airways and
asthma [24]. Recombinant human IL-11 administration
to activated macrophages in vitro has been shown to in-
hibit TNFα, IL-1β, IL-12, and nitric oxide production
[15]. IL-11 has also been shown to play a role in de-
creasing mucosal damage in inflammatory bowel disease
[25] and decreasing the severity of acute necrotizing
pancreatitis [26]. Given the significant role of other cyto-
kines in the gp130 family and evidence pointing to an
anti-inflammatory role and effect on promoting oligo-
dendrocyte survival, IL-11 was addressed in this study.
We hypothesized that knocking out IL-11Rα, and thus
eliminating IL-11 signaling, would result in decreased
functional recovery and poorer histopathological out-
comes due to increased inflammation after injury and
poor oligodendrocyte survival. In contrast to our initial
hypothesis, we found that knocking out IL-11Rα did not
result in significant differences in functional recovery
and histopathology after SCI.
While our results indicate that IL-11 is not a dominant
player in the pathophysiology of SCI, our findings do
not necessarily indicate that IL-11 signaling does not
play any role in this condition. We did demonstrate for
the first time that SCI affects the expression of IL-11
and its receptor, IL-11Rα, in spinal cord tissue. Previous
research has demonstrated that IL-11 must first bind to
IL-11Rα, and this complex of cytokine and receptor
Figure 6 Early neutrophil infiltration into the injured spinal
cord does not appear to differ between wild-type and IL-11Rα-
deficient mice. Myeloperoxidase (MPO) activity in the spinal cord is
not significantly different between injured wild-type (n = 5) and
injured IL-11Rα-deficient (n = 5) mice 24 hours post-SCI, although
injured mice demonstrate significantly greater MPO activity
compared to uninjured wild-type control mice (n = 5). Data
represent mean ± SEM (error bars). *P <0.05 (one-way ANOVA
followed by post hoc Bonferroni test).
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subunit then recruits the signaling gp130 receptor sub-
unit [27]. This is important given that, while gp130 is
ubiquitously expressed, the expression of α-receptors is
restricted and tightly regulated, which limits the types of
cells that respond to different members of the gp130
family [27].
In the current paper, we demonstrate that both IL-11
and IL-11Rα expression in the spinal cord change in re-
sponse to injury thus suggesting that IL-11 and IL-11Rα
play a role in SCI at the level of the spinal cord tissue.
Interestingly, the gene expression profile of IL-11 differs
from its receptor both in magnitude and in its temporal
pattern with peak gene expression of IL-11 at approxi-
mately 24 hours post-SCI (twentyfold increase) while
IL-11Rα gene expression peaks much later (twofold in-
crease). To date, we have not come across many studies
of gp130 cytokines that have documented the expression
patterns of both the cytokine and its associated α-
receptor in SCI, making it difficult to compare with other
members in the family. However, given the necessity of
the α-receptor in signaling, it is reasonable to propose
that the expression of the α-receptor acts as the limiting
factor in IL-11 signaling. As a result, given that the peak
in IL-11Rα expression is on the order of days after SCI,
this suggests that IL-11 signaling may not play as signifi-
cant a role in the acute inflammatory response after in-
jury, but more in the long-term sequelae such as
oligodendrocyte survival. The possibility that IL-11 sig-
naling may not play as significant a role in the acute in-
flammatory response was demonstrated in the data, with
no significant differences between wild-type and knock-
out injured mice in myeloperoxidase activity levels at
24 hours post-SCI, when neutrophil infiltration into the
cord is at its peak [23]. TNFα and IL-1β both have been
shown to recruit neutrophils and macrophages into the
spinal cord [23]. TNFα and IL-1β gene expression in the
spinal cord have been shown to peak at approximately
one hour and twelve hours, respectively, post-SCI with
decreases in expression to basal levels by seven days in
the mouse except for TNFα, which appears to peak
again at fourteen and twenty-eight days post-SCI [28].
Therefore, despite evidence that IL-11 negatively regu-
lates these cytokines [29], IL-11 signaling in the spinal
cord in vivo after injury falls outside the appropriate
window to have a significant effect on their expression
in the early acute phases after injury to affect the recruit-
ment of inflammatory cells such as neutrophils.
As a result, despite clear changes in gene and protein
expression of IL-11 and IL-11Rα, we found that there
were no significant differences in functional recovery be-
tween injured wild-type and injured IL-11Rα knockout
mice. There were no significant differences in both the
BMS hindlimb score and BMS subscore analysis between
wild-type and knockout mice up to six weeks post-SCI.
Further, hindlimb motor function was assessed at six
weeks using the CatWalk gait analysis system. The Cat-
Walk gait analysis system assesses motor parameters not
detected using the BMS, and again, no significant differ-
ences were detected in print width, print length, stride
length, base of support, swing time, and regularity index.
This is in contrast to other members of the gp130 family
of cytokines including IL-6 and LIF, which have demon-
strated significant effects on motor recovery. Mice trea-
ted with an antibody against the IL-6 receptor were
found to have significantly better functional recovery
compared to control mice and reduced glial scar tissue
[7]. Mice treated with LIF have demonstrated increases
in proliferation of microglia/macrophages that corre-
sponded with significant decreases in motor function
compared to control mice [11]. This is in contrast to an-
other study that found significantly better motor per-
formance in mice that received intraperitoneal delivery
of LIF relative to minocycline- or albumin/PBS control-
injected mice after hemisection cord injury [30]. It is un-
clear as to exactly why IL-11 signaling does not appear
to play as significant role in affecting functional recovery
after SCI. One possibility, as stated beforehand, could be
the later increase in expression of IL-11Rα after SCI,
which limits IL-11 signaling in the spinal cord until later
time points after injury. Both IL-6 and LIF gene expres-
sion peak in the more acute phases after injury with IL-6
and LIF peaking at twelve hours and six hours, respect-
ively. While the gene expression of the receptors for IL-
6 and LIF have not been documented and thus cannot
directly be compared with that of IL-11, the peak gene
expression of IL-11 at 24 hours post-SCI is still later
than either IL-6 or LIF, suggesting that IL-6 and LIF, in
combination with other pro-inflammatory cytokines,
may play more dominant roles in the early setup of the
molecular and cellular environment in the spinal cord
after injury before IL-11 signaling can come into effect.
In support of the lack of significant differences in
motor recovery between wild-type and knockout mice,
we found no significant differences in axonal conduction
and histopathology in the injured spinal cord. This sup-
ports the idea that IL-11 may not play as dominant a
role in the early inflammatory signaling after injury as
other pro-inflammatory cytokines and other cytokines in
the gp130 family, especially with similar amounts of
scarring between wild-type and knockout mice. How-
ever, this finding is in contrast to previous studies dem-
onstrating a role for IL-11 in promoting oligodendrocyte
viability and maturation in vitro [16,17]. Based on these
studies, it was originally hypothesized the IL-11Rα
knockout mice would demonstrate poorer axonal con-
duction and white matter sparing relative to wild-type
mice. However, the absence of significant differences be-
tween injured wild-type and knockout mice suggests the
Cho et al. Journal of Neuroinflammation 2012, 9:134 Page 10 of 12
http://www.jneuroinflammation.com/content/9/1/134
presence of a protective factor. Mice treated with LIF
have demonstrated decreases in oligodendrocyte apop-
tosis after SCI [10,12]. In this study, LIF may have pro-
vided the protective signaling to prevent further
demyelination and loss of function after SCI. This sug-
gests redundancy of function of the gp130 cytokines in
SCI and perhaps points to an innate protective mechan-
ism to prevent further damage should one cytokine
pathway be nonfunctional.
There has been extensive debate about the use of
knockout models in addressing injury to the central ner-
vous system. This has been demonstrated most recently
with the conflicting results surrounding the effect of
Nogo, myelin-associated glycoprotein (MAG), and oligo-
dendrocyte myelin glycoprotein (OMgp) in axonal re-
generation after injury to the brain and spinal cord
based on genetic knockout mice models [31]. It is pos-
sible that knocking out the IL-11Rα gene in the embry-
onic stage may have resulted in developmental
compensation by other cytokines in the gp130 family
that may have masked any potential detrimental effects
ablating IL-11 signaling may have in SCI. Thus, it is im-
portant to note that although the results of this study
did not demonstrate significant functional differences
between knockout and wild-type mice, IL-11 may still
play an important role in the pathophysiology of spinal
cord injury that were not detected in this study.
To further address the role of IL-11 signaling in SCI, it
is suggested that pharmacological methods be imple-
mented. Studies addressing both pharmacological inhib-
ition of IL-11 or IL-11Rα, using neutralizing antibodies,
or overexpression/administration of IL-11 should be car-
ried out to see if differences in functional recovery and
histopathology may occur after SCI. In this case, the
question of compensation present in the genetic model
can be circumvented. Further studies characterizing the
role of IL-11 signaling in oligodendrocyte viability, mat-
uration, and myelin formation in in vivo models of SCI
would also provide valuable insights into the role of this
cytokine.
To date, this is the first study to examine the potential
role of IL-11 signaling in the pathophysiology of SCI.
Despite the lack of significant differences in functional
recovery after SCI between wild-type and knockout
mice, clear changes in expression of IL-11 and its α-
receptor suggest that IL-11 signaling plays a role in SCI.
The results of this study suggest that IL-11 does not play
a major role in the pathophysiology of SCI but, instead,
plays a role secondary to other cytokines including
TNFα, IL-1β, IL-6, and LIF and that there is redundancy
in the spinal cord cytokine network. The timing of ex-
pression is a key factor in determining the ultimate role
of a cytokine after SCI, especially in relation to other
cytokines and in determining which cytokines’ effects
will predominate in the pathophysiology of the injury.
Possible developmental compensation in the knockout
model used for the study suggests that we must exercise
caution in concluding that the null results of this study
suggest that IL-11 does not play a role in SCI. Future
studies can bypass this limitation through the use of
pharmacologic inhibition of both IL-11 and its receptor.
This study demonstrates that despite sharing a com-
mon signal transducing receptor, members of the gp130
family of cytokines play different roles in SCI. Future
therapies should focus on modulating the cytokines
shown to have significant ramifications on functional re-
covery as these will likely result in the greatest yield. As
we begin to understand the major players in the patho-
physiology of SCI, we can move forward to design more
specific therapies to improve functional recovery.
Conclusions
Our study suggests that IL-11 signaling may not play a
major role in the pathophysiology of SCI. This study is
the first study to address the role of IL-11 in SCI and
hopefully will provide a basis for future research in
understanding the role of the gp130 family of cytokines
in inflammation after injury. Ultimately, this understand-
ing will hopefully lead to better and more specific ther-
apies aimed at modulating cytokine signaling and
decreasing damaging inflammatory processes after SCI.
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